Libidon is a peptide bioregulator made from prostate tissue, and it’s studied for its support of prostate gland function and normal urinary flow. Prostate tissue changes with age in most men, and the peptide signals that tissue depends on decline right alongside it.
Libidon sits in an unusual spot within the bioregulator category. Where most tissue peptides have been tested mainly in animals and cell cultures, prostate peptides carry something rarer: published human data from urology clinics.
Key Takeaways
The Short Version
Libidon is a prostate peptide bioregulator studied for its support of prostate gland function and normal urination in aging men.
Prostate peptide preparations have been evaluated in human urology research, including studies in men aged 51 to 89.
Bioregulators are tissue-specific: in side-by-side testing, prostate peptides stimulated prostate tissue and not other tissues.
Choose a product with third-party testing, a published Certificate of Analysis, and the peptide source clearly named on the label.
What Libidon Is
Libidon is a short-chain peptide complex extracted from the prostate glands of young animals. It’s designated A-16 in the Khavinson bioregulator system, the catalogue of tissue-specific peptide complexes developed over three decades at the St. Petersburg Institute of Bioregulation and Gerontology (institutional overview).
BioLongevity sells it as BioProstate (A-16).
Every tissue makes its own regulatory peptides. Those peptides tell cells in that tissue how to behave: when to divide, when to make protein, when to stop. Production drops as we age. A bioregulator reintroduces peptides sourced from the matching tissue.
New to the category? Start with our explainer on what peptide bioregulators are.
How Prostate Peptides Work
Short peptides work inside the cell, not on its surface.
They’re small enough to cross the cell membrane using ordinary peptide transporters. The POT family (PEPT1, PEPT2) and LAT carriers are what a 2022 review identifies as the likely route into the cell. Once inside, they reach the nucleus and influence which genes get transcribed.
Related short peptides have been shown to shift the expression of genes tied to cell renewal and aging, including IGF1, FOXO1, and TERT in human stem cell cultures.
The tissue-specific part is the piece that distinguishes bioregulators from generic supplements.
Researchers ran a direct comparison. They took polypeptides extracted from seven tissues (prostate, pineal, liver, heart, cartilage, brain cortex, and thymus) and applied each to matching organotypic tissue cultures from young and old rats. Each polypeptide selectively stimulated growth in its own tissue, raising the proliferation marker PCNA and lowering p53. Prostate peptides acted on prostate tissue. Not on the others.
That’s the mechanism, demonstrated cleanly.
What the Research Says About Libidon Peptide Benefits
The prostate peptide literature is stronger on human data than most of the bioregulator catalogue.
Human urology research
The prostate peptide preparation studied in this literature is Prostatilen, made from bovine prostate regulatory peptides, the same tissue source Libidon draws on.
In one report from the urological clinic at St. Petersburg State Medical University, researchers reviewed outcomes in 96 men aged 51 to 89 and found prostate peptide administration relieved symptoms associated with restricted urinary flow. A follow-up clinical study using repeated 15-day courses every three months reported reduced symptom scores and lower residual urine volume.
A much larger clinical series covering 1,115 patients reported effects on microcirculation and inflammatory markers in the prostate and kidney.
These are Russian-language clinical reports, most without placebo control, and they should be read as promising rather than definitive. But they are human studies on the exact tissue peptide, which is more than most supplement ingredients can say.
Randomized, placebo-controlled evidence in the category
The strongest study design in this space comes from an adjacent bioregulator. A blind, randomized, placebo-controlled trial tested a bladder peptide bioregulator in men aged 62 to 83 with prostatic enlargement. Course treatment significantly improved core urination parameters and quality of life, and the improvement held for a month after treatment ended. No adverse effects were recorded.
That trial is about a bladder peptide, not a prostate one. We’re flagging that rather than blurring it. What it demonstrates is that the bioregulator approach can hold up under a placebo-controlled design in exactly the population Libidon is designed for.
Animal research
In rats, a prostate peptide preparation combined with a zinc complex produced a pronounced organotropic anti-inflammatory effect, reduced protein in urine, normalized urination, showed antioxidant activity, and raised blood testosterone. This is animal data, and testosterone effects in rats don’t translate directly to men. It’s a mechanism worth watching.
Who Libidon Is For
The reader profile here is specific.
- Men over 45 who want to support prostate function proactively rather than wait.
- Longevity-minded men building a systems-based routine, one organ at a time.
- Men who read labels and want to know exactly what tissue a peptide came from and what testing backs it.
A note that matters: changes in urination are worth a conversation with a clinician, not a supplement guess. Get a baseline. Then decide what belongs in your routine.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
What to Look for in a Prostate Peptide Bioregulator
| What to check | Why it matters |
|---|---|
| Third-party testing | Verifies the peptide content matches the label |
| Certificate of Analysis | Batch-level proof of identity, purity, and contaminant screening |
| Named tissue source | Tissue specificity is the mechanism, so it should be printed on the label |
| U.S. GMP manufacturing | Manufacturing standards you can trace |
| Transparent dosing | No proprietary blends hiding the actual amount |
BioLongevity publishes a Certificate of Analysis for every batch. That’s the document that turns a claim into something you can check.
Frequently Asked Questions
Does Libidon affect libido?
The name comes from the Latin root, not from a sexual performance claim. Libidon is studied for prostate gland function and urinary support. Any broader effect on hormones or sexual health in humans has not been established, and we won’t imply otherwise.
Is Libidon the same as Prostatilen?
They’re closely related. Both are peptide preparations derived from prostate tissue. Prostatilen is the name used in the Russian clinical literature; Libidon is the oral bioregulator format.
How is Libidon taken?
Bioregulators are traditionally taken in cycles rather than continuously. Follow the product label unless your clinician recommends otherwise.
Can Libidon be stacked with other bioregulators?
Yes. Tissue-specific peptides are commonly combined by system. Men often pair a prostate bioregulator with others in the bioregulator collection.
How strong is the evidence?
Honestly: better than most of the bioregulator catalogue, and still early. There’s human clinical data on the prostate peptide, a placebo-controlled trial on a neighboring bioregulator, and clear mechanistic work on tissue specificity. Large modern RCTs on Libidon itself don’t exist yet.
Where to Start
Prostate health is one of the few areas where men reliably wait too long. The tissue changes quietly, and by the time symptoms are obvious, the easy window has closed.
BioProstate (A-16) is BioLongevity’s prostate peptide bioregulator, formulated with the natural prostate peptide complex, third-party tested, and made in the U.S. under GMP standards. Every batch has a published Certificate of Analysis, so you can verify what’s in the capsule before you take it.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Khavinson VK, Ryzhak GA, Mikhailova ON. Saint Petersburg Institute of Bioregulation and Gerontology: achievements and prospects. Advances in Gerontology. 2013;26(1):11-19. PubMed
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences. 2022;23(14):7733. DOI
- Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanyushin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Molecular Biology Reports. 2020;47(6):4323-4329. DOI
- Ryzhak AP, Chalisova NI, Lin’kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. Polypeptides influence on tissue cell cultures regeneration of various age rats. Advances in Gerontology. 2015;28(1):97-103. PubMed
- Al’-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz’min IV. Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia. Urologiia. 2005;(5):25-26. PubMed
- Al’-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz’min IV, Chushkin KA. Prostatilen treatment of prostatic adenoma. Urologiia. 2006;(6):22, 25-26. PubMed
- Al’-Shukri SKh, Bobkov IuA, Gorbachev AG, Kuz’min IV, Tkachuk VN. Our experience in the use of prostatilen in urology. Urologiia. 2003;(6):32-36. PubMed
- Gomberg VG, Ryzhak VG, Liutov RV. Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia. Advances in Gerontology. 2013;26(3):476-480. PubMed
- Savateeva-Liubimova TN, Sivak KV, Malinin VV. Effect of prostatilen AC suppositories on course of experimental prostatitis. Urologiia. 2012;(4):50-52, 54. PubMed